Christopher J. Packard
#106,782
Most Influential Person Now
Christopher J. Packard's AcademicInfluence.com Rankings
Christopher J. Packardmedical Degrees
Medical
#1356
World Rank
#1683
Historical Rank
Cardiology
#97
World Rank
#99
Historical Rank
Public Health
#163
World Rank
#170
Historical Rank
Epidemiology
#188
World Rank
#200
Historical Rank
Christopher J. Packardphilosophy Degrees
Philosophy
#4351
World Rank
#6833
Historical Rank
Logic
#1831
World Rank
#2678
Historical Rank
Download Badge
Medical Philosophy
Christopher J. Packard's Degrees
- Bachelors Biology University of California, Berkeley
- Doctorate Medicine University of California, San Francisco
Similar Degrees You Can Earn
Why Is Christopher J. Packard Influential?
(Suggest an Edit or Addition)Christopher J. Packard's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia (1995) (5842)
- Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial (2002) (3200)
- Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. (1995) (2355)
- Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel (2017) (1817)
- Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials (2010) (1770)
- Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study (2003) (1584)
- Major lipids, apolipoproteins, and risk of vascular disease. (2009) (1563)
- West of Scotland Coronary Prevention Study: Identification of high-risk groups and comparison with other cardiovascular intervention trials (1996) (1291)
- C-reactive protein, fibrinogen, and cardiovascular disease prediction. (2012) (952)
- Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study (2001) (896)
- Plasma Leptin and the Risk of Cardiovascular Disease in the West of Scotland Coronary Prevention Study (WOSCOPS) (2001) (859)
- Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). (1998) (810)
- Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. (2000) (771)
- C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. (2002) (754)
- Overproduction of large VLDL particles is driven by increased liver fat content in man (2006) (638)
- Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies (2010) (588)
- Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study (2007) (579)
- Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. (1994) (551)
- Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel (2020) (541)
- Rare and low-frequency coding variants alter human adult height (2016) (511)
- Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies (2008) (499)
- The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. (1999) (482)
- Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty‐person/ten‐country panel (2006) (478)
- Lipid-related markers and cardiovascular disease prediction. (2012) (457)
- Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease (2016) (434)
- Effects of dietary polyunsaturated and saturated fat on the properties of high density lipoproteins and the metabolism of apolipoprotein A-I. (1978) (433)
- Effect of Pravastatin on Coronary Disease Events in Subgroups Defined by Coronary Risk Factors: The Prospective Pravastatin Pooling Project (2000) (422)
- Lipoprotein heterogeneity and apolipoprotein B metabolism. (1997) (410)
- Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials (2019) (377)
- Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. (2004) (376)
- Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) (356)
- Effects of saturated and polyunsaturated fat diets on the chemical composition and metabolism of low density lipoproteins in man. (1980) (354)
- Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis (2018) (340)
- Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism. (1980) (333)
- Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM (1997) (326)
- Lipoprotein Subfraction Concentrations in Preeclampsia: Pathogenic Parallels to Atherosclerosis (1997) (326)
- Metabolism of apolipoprotein B in large triglyceride-rich very low density lipoproteins of normal and hypertriglyceridemic subjects. (1984) (315)
- Long-term follow-up of the West of Scotland Coronary Prevention Study. (2007) (280)
- Pravastatin and cognitive function in the elderly. Results of the PROSPER study (2009) (255)
- Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease (2000) (254)
- Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. (1979) (254)
- Postprandial lipemia, fenofibrate and coronary artery disease. (1990) (248)
- Overproduction of VLDL1 Driven by Hyperglycemia Is a Dominant Feature of Diabetic Dyslipidemia (2005) (240)
- Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. (1996) (236)
- Rapid isolation of low density lipoprotein (LDL) subfractions from plasma by density gradient ultracentrifugation. (1990) (236)
- Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension (2016) (234)
- Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions. (2000) (232)
- Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. (2003) (232)
- Lipoprotein subfraction changes in normal pregnancy: threshold effect of plasma triglyceride on appearance of small, dense low density lipoprotein. (1997) (219)
- Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk (2017) (216)
- Blood Rheology, Cardiovascular Risk Factors, and Cardiovascular Disease: The West of Scotland Coronary Prevention Study (2000) (215)
- Regulation of plasma HDL cholesterol and subfraction distribution by genetic and environmental factors. Associations between the TaqI B RFLP in the CETP gene and smoking and obesity. (1994) (208)
- Accumulation of large very low density lipoprotein in plasma during intravenous infusion of a chylomicron-like triglyceride emulsion reflects competition for a common lipolytic pathway. (1996) (200)
- SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. (2021) (200)
- Effect of Pravastatin on Rate of Kidney Function Loss in People With or at Risk for Coronary Disease (2005) (200)
- Effects of insulin and acipimox on VLDL1 and VLDL2 apolipoprotein B production in normal subjects. (1998) (196)
- Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure underpinning obesity (2017) (193)
- Insight into the nature of the CRP-coronary event association using Mendelian randomization. (2006) (191)
- Inheritance of coronary artery disease in men: an analysis of the role of the Y chromosome (2012) (191)
- Familial combined hyperlipidaemia linked to the apolipoprotein AI–CIII–AIV gene cluster on chromosome 11q23q–q24 (1991) (191)
- Metabolic basis of hypotriglyceridemic effects of insulin in normal men. (1997) (187)
- Subpopulations of apolipoprotein A-I in human high-density lipoproteins. Their metabolic properties and response to drug therapy. (1983) (187)
- Socio-economic status is associated with epigenetic differences in the pSoBid cohort. (2012) (181)
- Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels (2006) (180)
- Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters (2001) (178)
- High-Sensitivity Cardiac Troponin, Statin Therapy, and Risk of Coronary Heart Disease (2016) (177)
- Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. (2008) (176)
- Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance (2007) (172)
- Receptor-mediated low density lipoprotein catabolism in man. (1979) (167)
- Effect of pravastatin in people with diabetes and chronic kidney disease. (2005) (163)
- Effect of sex and genotype on cardiovascular biomarker response to fish oils: the FINGEN Study. (2008) (159)
- Effects of prior moderate exercise on postprandial metabolism and vascular function in lean and centrally obese men. (2004) (156)
- The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases (2007) (155)
- Influence of apolipoprotein E polymorphism on apolipoprotein B-100 metabolism in normolipemic subjects. (1991) (153)
- Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. (2014) (153)
- Lipoprotein metabolism in hepatic lipase deficiency: studies on the turnover of apolipoprotein B and on the effect of hepatic lipase on high density lipoprotein. (1988) (151)
- The role of small, dense low density lipoprotein (LDL): a new look. (2000) (151)
- Potential pathogenic roles of aberrant lipoprotein and fatty acid metabolism in pre‐eclampsia (1996) (147)
- Obesity is associated with fatal coronary heart disease independently of traditional risk factors and deprivation (2011) (145)
- Relations between plasma lipids and postheparin plasma lipases and VLDL and LDL subfraction patterns in normolipemic men and women. (1995) (145)
- Independent mutations at codon 3500 of the apolipoprotein B gene are associated with hyperlipidemia. (1995) (140)
- Testing cognitive function in elderly populations: the PROSPER study (2002) (139)
- Interleukin-6, Fibrin D-Dimer, and Coagulation Factors VII and XIIa in Prediction of Coronary Heart Disease (2004) (136)
- Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation. (2000) (134)
- Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia. (1993) (131)
- Effects of cholestyramine on receptor-mediated plasma clearance and tissue uptake of human low density lipoproteins in the rabbit. (1980) (131)
- Effects of simvastatin on apoB metabolism and LDL subfraction distribution. (1993) (130)
- C-Reactive Protein and Prediction of Coronary Heart Disease and Global Vascular Events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) (2007) (130)
- Determinants of LDL subfraction distribution and concentrations in young normolipidemic subjects. (1994) (128)
- Effect of Insulin Therapy on Metabolic Fate of Apolipoprotein B–Containing Lipoproteins in NIDDM (1990) (127)
- Accelerated Telomere Attrition Is Associated with Relative Household Income, Diet and Inflammation in the pSoBid Cohort (2011) (127)
- The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials (2015) (123)
- Fasting and postprandial determinants for the occurrence of small dense LDL species in non-insulin-dependent diabetic patients with and without hypertriglyceridaemia: the involvement of insulin, insulin precursor species and insulin resistance. (1995) (122)
- Plasma Lipoproteins and Apolipoproteins as Predictors of Cardiovascular Risk and Treatment Benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) (2005) (122)
- A new combined multicompartmental model for apolipoprotein B-100 and triglyceride metabolism in VLDL subfractions Published, JLR Papers in Press, October 16, 2004. DOI 10.1194/jlr.M400108-JLR200 (2005) (120)
- A polymorphism of the cholesteryl ester transfer protein gene predicts cardiovascular events in non-smokers in the West of Scotland Coronary Prevention Study. (2003) (120)
- Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease (2003) (120)
- Unraveling the directional link between adiposity and inflammation: a bidirectional Mendelian randomization approach. (2009) (120)
- Serial Metabolic Measurements and Conversion to Type 2 Diabetes in the West of Scotland Coronary Prevention Study (2007) (120)
- Interaction of very-low-density, intermediate-density, and low-density lipoproteins with human arterial wall proteoglycans. (1997) (117)
- Small dense low-density lipoprotein and its role as an independent predictor of cardiovascular disease (2006) (117)
- Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. (2019) (115)
- Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society (2021) (115)
- The hepatobiliary axis and lipoprotein metabolism: effects of bile acid sequestrants and ileal bypass surgery. (1982) (112)
- Are Markers of Inflammation More Strongly Associated with Risk for Fatal Than for Nonfatal Vascular Events? (2009) (109)
- Dietary Fructose and the Metabolic Syndrome (2019) (105)
- Effects of bezafibrate on receptor-mediated and receptor-independent low density lipoprotein catabolism in type II hyperlipoproteinaemic subjects. (1982) (105)
- Separating the Mechanism-Based and Off-Target Actions of Cholesteryl Ester Transfer Protein Inhibitors With CETP Gene Polymorphisms (2010) (104)
- Early life socioeconomic adversity is associated in adult life with chronic inflammation, carotid atherosclerosis, poorer lung function and decreased cognitive performance: a cross-sectional, population-based study (2011) (102)
- Lipid and lipoprotein concentrations in pregnancies complicated by intrauterine growth restriction. (1999) (101)
- CD36 and SR-BI are involved in cellular uptake of provitamin A carotenoids by Caco-2 and HEK cells, and some of their genetic variants are associated with plasma concentrations of these micronutrients in humans. (2013) (100)
- Cholesterol feeding increases low density lipoprotein synthesis. (1983) (100)
- Polymorphisms in the gene coding for cholesteryl ester transfer protein are related to plasma high-density lipoprotein cholesterol and transfer protein activity. (1990) (95)
- Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. (2000) (94)
- Fenofibrate Reduces Low Density Lipoprotein Catabolism in Hypertriglyceridemic Subjects (1985) (94)
- Low-density lipoprotein metabolism in the nephrotic syndrome. (1990) (93)
- A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease (2016) (92)
- Contribution of apolipoprotein E genotype and docosahexaenoic acid to the LDL-cholesterol response to fish oil. (2010) (92)
- Metabolism of apolipoprotein B-containing lipoproteins in subjects with nephrotic-range proteinuria. (1991) (92)
- Non-HDL cholesterol as a measure of atherosclerotic risk. (2004) (91)
- Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study (2013) (91)
- Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy 20-Year Follow-Up of West of Scotland Coronary Prevention Study (2016) (90)
- Causes and Consequences of Hypertriglyceridemia (2020) (90)
- Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia. (2003) (89)
- Leptin Predicts Diabetes but Not Cardiovascular Disease (2009) (88)
- Peroxisome proliferator activated receptor delta genotype in relation to cardiovascular risk factors and risk of coronary heart disease in hypercholesterolaemic men (2003) (88)
- Metabolism of VLDL and LDL subclasses. (1994) (86)
- Low density lipoprotein metabolism in a family of familial hypercholesterolemic patients. (1976) (86)
- The effects of cholestyramine on high density lipoprotein metabolism. (1979) (86)
- Apolipoprotein A and B (Sf 100-400) metabolism during bezafibrate therapy in hypertriglyceridemic subjects. (1984) (85)
- The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential (2019) (84)
- Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study. (1997) (81)
- Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates. (2002) (81)
- Sensitive methods to study human apolipoprotein B metabolism using stable isotope-labeled amino acids. (1996) (79)
- Atherogenic lipoprotein phenotype in Type 2 diabetes: reversal with micronised fenofibrate (1999) (79)
- Genetic variation in the interleukin-1 beta-converting enzyme associates with cognitive function. The PROSPER study. (2008) (78)
- Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER. (2008) (76)
- Catabolic rate of low density lipoprotein is influenced by variation in the apolipoprotein B gene. (1988) (74)
- Intravascular transfer contributes to postprandial increase in numbers of very-low-density hepatitis C virus particles. (2010) (74)
- Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke (2005) (74)
- Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and (2017) (74)
- Circulating Interleukin-10 and Risk of Cardiovascular Events: A Prospective Study in the Elderly at Risk (2011) (74)
- A Longitudinal Study of the Relationships between Haemostatic, Lipid, and Oestradiol Changes during Normal Human Pregnancy (1999) (73)
- Overproduction of small very low density lipoproteins (Sf 20-60) in moderate hypercholesterolemia: relationships between apolipoprotein B kinetics and plasma lipoproteins. (1995) (72)
- Blood Pressure Variability and Cardiovascular Risk in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) (2012) (71)
- The hypolipidemic action of probucol: a study of its effects on high and low density lipoproteins. (1983) (70)
- Effects of short-term detraining on postprandial metabolism, endothelial function, and inflammation in endurance-trained men: dissociation between changes in triglyceride metabolism and endothelial function (2003) (70)
- Prospective analysis of the association of infection with CagA bearing strains of Helicobacter pylori and coronary heart disease (2002) (69)
- Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life (2018) (68)
- ‘Highest risk–highest benefit’ strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies (2017) (67)
- Thyroid replacement therapy and its influence on postheparin plasma lipases and apolipoprotein-B metabolism in hypothyroidism. (1993) (66)
- Differences in atherosclerosis according to area level socioeconomic deprivation: cross sectional, population based study (2009) (66)
- Hepatic production of VLDL1 but not VLDL2 is related to insulin resistance in normoglycaemic middle-aged subjects. (2004) (65)
- Long Term Safety and Efficacy of Lowering LDL Cholesterol With Statin Therapy: 20-Year Follow-Up of West of Scotland Coronary Prevention Study (2016) (65)
- Dynamic properties of human high density lipoprotein apoproteins. (1978) (65)
- The Microsomal Triglyceride Transfer Protein Gene-493T Variant Lowers Cholesterol But Increases the Risk of Coronary Heart Disease (2004) (63)
- Heterogeneity of apolipoprotein B-100-containing lipoproteins: what we have learnt from kinetic studies. (1998) (62)
- Abdominal obesity, impaired nonesterified fatty acid suppression, and insulin-mediated glucose disposal are early metabolic abnormalities in families with premature myocardial infarction. (1998) (62)
- Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy (2016) (61)
- Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD (2019) (60)
- Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West Of Scotland Coronary Prevention Study (WOSCOPS). (2002) (60)
- Exercise training has greater effects on insulin sensitivity in daughters of patients with type 2 diabetes than in women with no family history of diabetes (2008) (60)
- Effects of dietary monounsaturated fatty acids on lipoprotein concentrations, compositions, and subfraction distributions and on VLDL apolipoprotein B kinetics: dose-dependent effects on LDL. (2003) (59)
- Reduced Glomerular Filtration Rate and Its Association with Clinical Outcome in Older Patients at Risk of Vascular Events: Secondary Analysis (2009) (59)
- Lipoprotein-associated phospholipase A(2) as an independent predictor of coronary heart disease (2000) (59)
- Soluble ST2 Associates with Diabetes but Not Established Cardiovascular Risk Factors: A New Inflammatory Pathway of Relevance to Diabetes? (2012) (59)
- Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis (2016) (58)
- Understanding coronary heart disease as a consequence of defective regulation of apolipoprotein B metabolism. (1999) (58)
- Effects of pregnancy and lactation on plasma lipid and lipoprotein concentrations, lipoprotein composition and post-heparin lipase activities in Shetland pony mares. (1993) (58)
- Genetic variation at the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels, but does not significantly lower vascular disease risk in an elderly population. (2008) (57)
- Metabolism of apolipoproteins A‐I and A‐ll and its influence on the high density lipoprotein subfraction distribution in males and females (1978) (56)
- Socioeconomic status and telomere length: the West of Scotland Coronary Prevention Study (2009) (56)
- Metabolic heterogeneity in very low-density lipoproteins. (1987) (56)
- Remodeling of cerebrospinal fluid lipoprotein particles after human traumatic brain injury. (2003) (55)
- Lipoprotein (a) levels in normal pregnancy and in pregnancy complicated with pre-eclampsia. (2000) (55)
- Lipoprotein (a), cholesterol and triglycerides in women with venous thromboembolism. (2000) (55)
- Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases. (2007) (55)
- Consumption of Fish Oil Providing Amounts of Eicosapentaenoic Acid and Docosahexaenoic Acid That Can Be Obtained from the Diet Reduces Blood Pressure in Adults with Systolic Hypertension: A Retrospective Analysis. (2016) (54)
- Plasma lipids, lipoproteins and post-heparin lipases in ponies with hyperlipaemia. (1992) (54)
- The inverse relationship between alanine aminotransferase in the normal range and adverse cardiovascular and non-cardiovascular outcomes. (2011) (53)
- Apolipoprotein B metabolism in normal, type IV and type V hyperlipoproteinemic subjects. (1980) (53)
- Discovery of rare variants associated with blood pressure regulation through meta-analysis of 1.3 million individuals (2020) (53)
- The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans (2020) (53)
- A comparison of two methods to investigate the metabolism of human apolipoproteins A-I and and A-II. (1978) (53)
- Effects of bezafibrate on apolipoprotein B metabolism in type III hyperlipoproteinemic subjects. (1986) (52)
- N-terminal pro-B-type natriuretic peptide and the prediction of primary cardiovascular events: results from 15-year follow-up of WOSCOPS (2012) (52)
- Receptor-independent catabolism of low density lipoprotein. Involvement of the reticuloendothelial system. (1982) (52)
- Effects of a moderate exercise session on postprandial lipoproteins, apolipoproteins and lipoprotein remnants in middle-aged men. (2006) (52)
- Effects of ciprofibrate on LDL metabolism in man. (1994) (51)
- Genetic variation at the NPC1L1 gene locus, plasma lipoproteins, and heart disease risk in the elderly[S] (2010) (51)
- Overview of fenofibrate. (1998) (51)
- The relationship between the cholesterol content and subfraction distribution of plasma high-density lipoproteins. (1980) (50)
- Effect of prior moderate exercise on postprandial metabolism in men with type 2 diabetes: heterogeneity of responses. (2007) (50)
- LDL-Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men with Primary Elevations of LDL-Cholesterol Levels of 190 mg/dL or Above: Analyses from the WOSCOPS 5-year Randomised Trial and 20-year Observational Follow-Up (2017) (50)
- Long-Term Effects of Statin Treatment in Elderly People: Extended Follow-Up of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) (2013) (48)
- Development and application of a multicompartmental model to study very low density lipoprotein subfraction metabolism. (1995) (48)
- Association Between ADAMTS1 Matrix Metalloproteinase Gene Variation, Coronary Heart Disease, and Benefit of Statin Therapy (2008) (47)
- Comparative effects of cerivastatin and fenofibrate on the atherogenic lipoprotein phenotype in proteinuric renal disease. (2001) (46)
- Cholesterol absorption and synthesis markers in individuals with and without a CHD event during pravastatin therapy: insights from the PROSPER trial (2010) (46)
- Smoking and plasma lipoprotein metabolism. (1995) (46)
- The isolation, characterisation and quantification of the equine plasma lipoproteins. (1991) (46)
- Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence (2019) (45)
- LDL subfractions and atherogenicity: an hypothesis from the University of Glasgow. (1996) (45)
- Collaborative pooled analysis of data on C-reactive protein gene variants and coronary disease: judging causality by Mendelian randomisation (2008) (45)
- Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity (2019) (45)
- Very low density and low density lipoprotein subfractions in type III and type IV hyperlipoproteinemia. Chemical and physical properties. (1979) (45)
- Exome Chip Meta-analysis Fine Maps Causal Variants and Elucidates the Genetic Architecture of Rare Coding Variants in Smoking and Alcohol Use (2019) (45)
- Effect of saturated and unsaturated fat diets on molecular species of phosphatidylcholine and sphingomyelin of human plasma lipoproteins. (1981) (44)
- Socioeconomic Deprivation and Cortical Morphology: Psychological, Social, and Biological Determinants of Ill Health Study (2013) (43)
- Genome of the Netherlands population-specific imputations identify an ABCA6 variant associated with cholesterol levels (2015) (43)
- The atherogenic lipoprotein phenotype: small dense LDL and lipoprotein remnants in nephrotic range proteinuria. (2001) (43)
- Activation of Hemostasis and Decline in Cognitive Function in Older People (2010) (43)
- A simultaneous study of the metabolism of apolipoprotein B and albumin in nephrotic patients. (1998) (42)
- A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): Screening Experience and Baseline Characteristics (2002) (42)
- SCREENING EXPERIENCE AND BASE-LINE CHARACTERISTICS IN THE WEST OF SCOTLAND CORONARY PREVENTION STUDY (1995) (41)
- Measurement and physiological significance of lipoprotein and hepatic lipase activities in preheparin plasma. (1995) (38)
- Effects of nicotinic acid therapy on high-density lipoprotein metabolism in type II and type IV hyperlipoproteinaemia. (1980) (38)
- Asp92Asn Polymorphism in the Myeloid IgA Fc Receptor Is Associated With Myocardial Infarction in Two Disparate Populations: CARE and WOSCOPS (2006) (38)
- Lipoprotein-associated phospholipase A2 as a biomarker of coronary heart disease and a therapeutic target (2009) (38)
- Psychological, social and biological determinants of ill health (pSoBid): Study Protocol of a population-based study (2008) (37)
- Understanding IMPROVE-IT and the cardinal role of LDL-C lowering in CVD prevention. (2014) (37)
- Phenotypes, genotypes and response to statin therapy (2004) (37)
- The Xba1 polymorphism of the apolipoprotein B gene influences the degradation of low density lipoprotein in vitro. (1989) (36)
- Measurement of receptor-independent lipoprotein catabolism using 1,2 cyclohexanedione-modified low density lipoprotein. (1982) (36)
- Fasting plasma glucose in non-diabetic participants and the risk for incident cardiovascular events, diabetes, and mortality: results from WOSCOPS 15-year follow-up. (2010) (36)
- Targeting RNA With Antisense Oligonucleotides and Small Interfering RNA: JACC State-of-the-Art Review. (2020) (36)
- Effect on saturated and unsaturated fat diets on lipid profiles of plasma lipoproteins. (1982) (35)
- The coffee diterpene cafestol increases plasma triacylglycerol by increasing the production rate of large VLDL apolipoprotein B in healthy normolipidemic subjects. (2001) (35)
- Biogerontology: Mechanisms and Interventions (2007) (35)
- Apolipoprotein E genotype and the cardiovascular disease risk phenotype: impact of sex and adiposity (the FINGEN study). (2012) (35)
- Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: opportunities and challenges (2021) (34)
- Personality, Socio-Economic Status and Inflammation: Cross-Sectional, Population-Based Study (2013) (34)
- The apolipoprotein B R3531C mutation. Characteristics of 24 subjects from 9 kindreds. (1999) (34)
- Statins : The HMG CoA reductase inhibitors in perspective (2003) (33)
- Effect of heparin-stimulated plasma lipolytic activity on VLDL APO B subclass metabolism in normal subjects. (1999) (33)
- Comparison of apolipoprotein B metabolism in familial defective apolipoprotein B and heterogeneous familial hypercholesterolemia. (2002) (33)
- KIF6, LPA, TAS2R50, and VAMP8 genetic variation, low density lipoprotein cholesterol lowering response to pravastatin, and heart disease risk reduction in the elderly. (2011) (32)
- Plasma C reactive protein concentration indicates a direct relation between systemic inflammation and social deprivation (2005) (32)
- Lipoprotein-associated phospholipase A(2), inflammatory biomarkers, and risk of cardiovascular disease in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). (2010) (32)
- Genome-Wide Study of Gene Variants Associated with Differential Cardiovascular Event Reduction by Pravastatin Therapy (2012) (32)
- Patients with nephrotic-range proteinuria have apolipoprotein C and E deficient VLDL1. (2000) (32)
- Contribution of the Receptor Pathway to Low Density Lipoprotein Catabolism in Humans: New Methods for Quantitation (1984) (31)
- Lipoprotein metabolism in the nephrotic syndrome. (1993) (30)
- New dimension of statin action on apoB atherogenicity (2003) (30)
- Genetic variation at the SLCO1B1 gene locus and low density lipoprotein cholesterol lowering response to pravastatin in the elderly. (2011) (30)
- Metabolism of apoB-100-containing lipoproteins in familial hyperchylomicronemia. (1993) (30)
- Interaction of personality traits with social deprivation in determining mental wellbeing and health behaviours. (2012) (30)
- Effects of colestipol alone and in combination with simvastatin on apolipoprotein B metabolism. (1996) (29)
- Cardiovascular risk factors and LDL subfraction profile in Type 2 diabetes mellitus subjects with good glycaemic control. (2001) (29)
- Role of apolipoprotein C‐III overproduction in diabetic dyslipidaemia (2019) (29)
- Effects of 1,2-cyclohexanedione modification on the metabolism of very low density lipoprotein apolipoprotein B: potential role of receptors in intermediate density lipoprotein catabolism. (1985) (28)
- Plasma lipid transport in the horse (Equus caballus). (1993) (28)
- Lipoprotein-Associated Phospholipase A2as an Independent Predictor of Coronary Heart Disease (2000) (27)
- A Comparison of Commercial Kits for the Measurement of Lipoprotein(a) (1991) (27)
- Sialic acid-containing components of lipoproteins influence lipoprotein-proteoglycan interactions. (1999) (27)
- Cardio-metabolic risk factors and cortical thickness in a neurologically healthy male population: Results from the psychological, social and biological determinants of ill health (pSoBid) study☆☆☆ (2013) (27)
- Regulation of small dense LDL concentration in Korean and Scottish men and women. (2002) (26)
- Investigation of human apoB48 metabolism using a new, integrated non‐steady‐state model of apoB48 and apoB100 kinetics (2019) (26)
- In vivo studies of VLDL metabolism and LDL heterogeneity. (1998) (26)
- Receptor-mediated catabolism and tissue uptake of human low density lipoprotein in the cholesterol-fed, atherosclerotic rabbit. (1982) (26)
- 25-Hydroxyvitamin D is lower in deprived groups, but is not associated with carotid intima media thickness or plaques: results from pSoBid. (2012) (25)
- High-density lipoprotein subfractions as measured by differential polyanionic precipitation and rate zonal ultracentrifugation. (1982) (24)
- Socioeconomic Status and the Cerebellar Grey Matter Volume. Data from a Well-Characterised Population Sample (2013) (24)
- Selective measurement of lipoprotein lipase and hepatic triglyceride lipase in heparinized plasma from horses. (1992) (24)
- The envirome and the connectome: exploring the structural noise in the human brain associated with socioeconomic deprivation (2013) (24)
- Apolipoprotein B48 metabolism in chylomicrons and very low‐density lipoproteins and its role in triglyceride transport in normo‐ and hypertriglyceridemic human subjects (2019) (23)
- Pharmacological approaches to the modulation of plasma cholesterol. (1988) (23)
- New metrics needed to visualize the long-term impact of early LDL-C lowering on the cardiovascular disease trajectory. (2015) (23)
- Receptor-independent low-density lipoprotein catabolism. (1986) (23)
- Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials (2022) (23)
- Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans. (2020) (23)
- The effects of a single nucleotide polymorphism in SLCO1B1 on the pharmacodynamics of pravastatin. (2012) (23)
- Microsomal triglyceride transfer protein -493T variant reduces IDL plus LDL apoB production and the plasma concentration of large LDL particles. (2006) (23)
- Effect of simvastatin on plasma lipid and lipoprotein concentrations and low-density lipoprotein metabolism in the nephrotic syndrome. (1992) (23)
- Point: status of lipid and lipoprotein standardization. (1997) (23)
- Haemochromatosis gene mutations and risk of coronary heart disease: a west of Scotland coronary prevention study (WOSCOPS) substudy (2004) (22)
- Long-term follow-up of lipid-lowering trials (2015) (22)
- Genetic invalidation of Lp-PLA2 as a therapeutic target: Large-scale study of five functional Lp-PLA2-lowering alleles (2016) (22)
- Early life socioeconomic status, chronic physiological stress and hippocampal N-acetyl aspartate concentrations (2012) (21)
- Beyond statins: what to expect from add-on lipid regulating therapy? (2013) (21)
- Effects of diabetes family history and exercise training on the expression of adiponectin and leptin and their receptors (2009) (21)
- The end of triglycerides in cardiovascular risk assessment? (1998) (20)
- HIGH DENSITY LIPOPROTEIN: GUARDIAN OF THE VASCULAR SYSTEM? (2002) (20)
- Influence of etofibrate on low density lipoprotein metabolism. (1988) (20)
- Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity (2017) (20)
- Probucol reduces plasma lipid peroxides in man. (1991) (19)
- Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects. (2019) (19)
- Genetic variants in the KIF6 region and coronary event reduction from statin therapy (2010) (19)
- Apolipoproteins: the new prognostic indicator? (2003) (18)
- Identification of a common low density lipoprotein receptor mutation (C163Y) in the west of Scotland. (1998) (18)
- Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia (2022) (18)
- Lipoprotein metabolism in familial hypercholesterolemia. (1989) (18)
- Effect of combined therapy with bezafibrate and cholestyramine on low-density lipoprotein metabolism in type IIa hypercholesterolemia. (1989) (17)
- Ultracentrifugal subfractionation of high-density lipoprotein. (1984) (17)
- Relationship between circulating microRNA-30c with total- and LDL-cholesterol, their circulatory transportation and effect of statins. (2017) (17)
- Is cholesterol the major lipoprotein risk factor in coronary heart disease?--a Franco-Scottish overview. (1997) (17)
- Low density lipoprotein metabolism. (1988) (17)
- Novel antecedent plasma biomarkers of cardiovascular disease: improved evaluation methods and comparator benchmarks raise the bar (2008) (17)
- Lipoprotein receptors and atherosclerosis. (1986) (16)
- At what level of coronary heart disease risk should a statin be prescribed? (2000) (16)
- C-reactive protein is an independent predictor of risk for the development of diabetes mellitus in the West of Scotland Coronary Prevention Study (2002) (16)
- Effects of dietary saturated and polyunsaturated fat on the metabolism of apolipoproteins A-I and B. Study of a patient with type IIb hyperlipoproteinaemia. (1978) (15)
- Are elevated circulating intercellular adhesion molecule 1 levels more strongly predictive of diabetes than vascular risk? Outcome of a prospective study in the elderly (2009) (15)
- Action of danazol on plasma lipids and lipoprotein metabolism. (1994) (15)
- Apolipoprotein B overproduction by the perfused liver of the St. Thomas' mixed hyperlipidemic (SMHL) rabbit. (1999) (15)
- Increased atherogenicity of low-density lipoprotein in heavy proteinuria. (1998) (14)
- ABCA1 gene variation and heart disease risk reduction in the elderly during pravastatin treatment. (2014) (14)
- Hepatitis C virus and atherosclerosis: A legacy after virologic cure? (2017) (14)
- Insulin resistance in the St. Thomas' mixed hyperlipidaemic (SMHL) rabbit, a model for familial combined hyperlipidaemia. (2000) (14)
- In vivo metabolism of apo A-I and apo A-II in subjects with apo A-I(Lys107-->0) associated with reduced HDL cholesterol and Lp(AI w AII) deficiency. (1997) (14)
- Serum lipid and lipoprotein profile of patients with glycogen storage disease types I, III and IX (2007) (13)
- Improving outcomes through statin therapy - a review of ongoing trials (2004) (13)
- Sensitive Mass Spectrometry Techniques for Measuring Metabolism of Human Apolipoprotein B In Vivo (1994) (13)
- High density lipoprotein metabolism in the horse (Equus caballus). (1993) (13)
- Comparative chemistry, pharmacology and mechanism of action of the statins (1999) (13)
- Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100- and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes. (2020) (13)
- LDL cholesterol: How low to go? (2017) (13)
- Management of hypercholesterolaemia in the patient with diabetes. (2002) (13)
- Regression of coronary atherosclerosis: is it possible? (1988) (13)
- Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. 1995. (2004) (13)
- Remodelling of cerebrospinal fluid lipoproteins after subarachnoid hemorrhage. (2003) (13)
- The role of stable isotopes in the investigation of plasma lipoprotein metabolism. (1995) (13)
- Lipid transport through the plasma: the metabolic basis of hyperlipidaemia. (1987) (12)
- Effects of liraglutide on the metabolism of triglyceride‐rich lipoproteins in type 2 diabetes (2021) (12)
- Association of oily fish intake, sex, age, BMI and APOE genotype with plasma long-chain n-3 fatty acid composition (2018) (12)
- Supraphysiological concentrations of estradiol in menopausal women given repeated implant therapy do not adversely affect lipid profiles. (2002) (12)
- The reticuloendothelial system and low density lipoprotein metabolism in the rabbit. (1982) (11)
- UK Food Standards Agency cis-monounsaturated fatty acid workshop report. (2002) (11)
- Effects of Dietary-Fat Saturation on the Composition of Very-Low-Density Lipoproteins and on the Metabolism of their Major Apoprotein, Apolipoprotein B (1978) (11)
- Influence of an asparagine to lysine mutation at amino acid 3516 of apolipoprotein B on low-density lipoprotein receptor binding. (2002) (11)
- Acipimox in combination with low dose cholestyramine for the treatment of type II hyperlipidaemia. (1990) (11)
- Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity (2018) (10)
- Influence of polymorphism Q3405E and mutation A3371V in the apolipoprotein B gene on LDL receptor binding. (1998) (10)
- Goals of statin therapy: three viewpoints. (2004) (10)
- Lipid-modifying effects of rosuvastatin in postmenopausal women with hypercholesterolemia who are receiving hormone replacement therapy* (2004) (10)
- Two subpopulations of intermediate density lipoprotein and their relationship to plasma triglyceride and cholesterol levels. (1997) (10)
- Diagnosis of type III hyperlipoproteinemia by chromatography of plasma lipoproteins on columns containing agarose. (1975) (10)
- Metabolic syndrome and diabetes mellitus. (2004) (10)
- The effect of omega-3 fatty acids on the atherogenic lipoprotein phenotype in patients with nephrotic range proteinuria. (2005) (9)
- Apolipoprotein B metabolism in man. (2009) (9)
- Th-W58:5 Lipoprotein-associated phospholipase A2 as a risk factor for coronary vascular disease in the elderly? (2006) (9)
- Comparative cellular uptake and cytotoxicity of a complex of daunomycin-low density lipoprotein in human squamous lung tumour cell monolayers. (1988) (9)
- Effect of cholestyramine on low-density lipoproteins. (1980) (8)
- Effect of Drugs on High Density Lipoprotein Metabolism (1980) (8)
- Characterisation of the lipoprotein structure in the St. Thomas' Mixed Hyperlipidaemic (SMHL) rabbit. (2005) (8)
- Sodium-lithium countertransport, sodium-hydrogen exchange and membrane microviscosity in patients with hyperlipidaemia. (1997) (8)
- A monoclonal-antibody-based immunoradiometric assay for apoprotein B in low-density lipoprotein. (1985) (8)
- Receptor-independent low-density lipoprotein catabolism. Evaluation of 2-hydroxyacetaldehyde-treated lipoprotein as a probe for its measurement. (1984) (8)
- Plasma apolipoprotein-B is an important risk factor for cardiovascular disease, and its assessment should be routine clinical practice. (2018) (8)
- Unpacking and Understanding the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Apolipoprotein B Metabolism (2017) (8)
- VLDL and LDL turnover: methods and clinical application (1992) (8)
- Determinants of Achieved LDL Cholesterol and “Non-HDL” Cholesterol in the Management of Dyslipidemias (2018) (8)
- Low-density lipoprotein metabolism following renal transplantation. (1985) (8)
- Unraveling the Directional Link between Adiposity and Inflammation: A Bidirectional Mendelian Randomization Approach. (2009) (7)
- Fractionation of cholesteryl ester rich intermediate density lipoprotein subpopulations by chondroitin sulphate. (2007) (7)
- Low Density Lipoprotein Uptake by Tumours (1982) (7)
- A triumvirate of targets in the prevention and treatment paradigm for cardiovascular disease. (2006) (7)
- Low-density lipoprotein receptor pathway in man: its role in regulating plasma low-density lipoprotein levels (1983) (7)
- CCR2 and coronary artery disease: a woscops substudy (2010) (7)
- Emerging Therapeutic Approaches to Treat Dyslipidemia (2014) (7)
- A poymorphism of the Cholesteryl Ester Transfer Protein (CETP) gene predicts Cardiovascular (CV) events in the West of Scotland Coronary Prevention Study (WOSCOPS) (2000) (7)
- Distinct patterns of heparin affinity chromatography VLDL1 and VLDL2 subfractions in the different dyslipidaemias. (2008) (7)
- Iatrogenic profound hypoalphalipoproteinaemia: an unrecognised cause of very low HDL cholesterol. (1995) (6)
- Triglyceride lowering 2.0: back to the future? (2019) (6)
- Remnants, LDL, and the Quantification of Lipoprotein-Associated Risk in Atherosclerotic Cardiovascular Disease (2022) (6)
- Very low density lipoprotein apolipoprotein B metabolism in humans (1988) (6)
- Effects of short-term detraining on postprandial metabolism, endothelial function, and inflammation in endurance-trained men: dissociation between changes in triglyceride metabolism and endothelial function. j.gill@bio.gla.ac.uk. (2003) (6)
- Low-Density-Lipoprotein Metabolism in Type n Hyperlipoproteinaemia (1976) (5)
- Strategies to alter the trajectory of atherosclerotic cardiovascular disease. (2019) (5)
- Preferential binding of small, dense LDL to human arterial proteoglycan (1994) (5)
- Prospective pravastatin pooling project: Relative risk reduction by baseline HDL and TG concentrations (2000) (5)
- Lipoprotein metabolism in lipase deficient states: studies in primary and secondary hyperlipidaemia. (1993) (5)
- Fibrates and HDL Cholesterol (1997) (5)
- The effect of hypolipidaemic drugs on subfractions of plasma low density lipoprotein (1990) (5)
- Familial hypobetalipoproteinemia due to a novel early stop mutation. (2008) (5)
- Omega-3 fatty acids improve postprandial lipaemia in patients with nephrotic range proteinuria. (2009) (5)
- LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial. (2021) (4)
- Establishing the metabolic basis of equine hyperlipidaemia (1990) (4)
- Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity (2018) (4)
- Pharmacological modification of lipoprotein metabolism. (1987) (4)
- Atherogenic lipid profile in elderly patients with ischaemic cerebrovascular disease (2000) (4)
- Dementia and statins (2001) (4)
- Metabolic Basis of the Atherogenic Lipoprotein Phenotype (1995) (4)
- An increased incidence of apolipoprotein E2/E2 and E4/E4 in retinitis pigmentosa (1993) (4)
- Goals of statin therapy: Three viewpoints (2002) (4)
- The effect of sotalol on plasma lipoproteins and apolipoproteins. (1986) (4)
- Electrophoretic mobility in agarose of very low density lipoprotein subfractions in type III hyperlipoproteinaemia. (1977) (4)
- LPA variants, risk of coronary disease, and estimated clinical benefit of lipoprotein(a) lowering therapies: A mendelian randomization analysis (2018) (4)
- Plasma lipid measurement (1990) (4)
- Evolution of the HMG CoA reductase inhibitors (statins) in cardiovascular medicine (2004) (4)
- An Overview of Lipoprotein Metabolism (1987) (3)
- Apolipoprotein B metabolism in dyslipidaemia and the effect of drugs. (1999) (3)
- Did we IMPROVE-IT: thoughts on LDL targeting post-trial? (2015) (3)
- Lipoprotein Metabolism and Atherogenesis (2000) (3)
- 3P-0718 Peroxisome proliferator activated receptor genotypes in relation to cardiovascular risk factors and risk of coronary heart disease in hypercholesterolaemic men (2003) (3)
- 11 – Low Density Lipoprotein Receptor Activity in Man (1982) (3)
- Postprandial metabolism of apolipoproteins B48, B100, C-III, and E in humans with APOC3 loss-of-function mutations (2022) (3)
- Atherogenicity of Triglyceride-Rich Lipoproteins: Clinical Aspects (1993) (3)
- Inflammatory mediators in atherosclerosis (2009) (3)
- Plasma lipids in retinitis pigmentosa (1987) (3)
- Atherosclerosis in perspective: the pathophysiology of human cholesterol metabolism (1992) (3)
- ApoE genotype and cardiovascular risk biomarkers: impact of gender and BMI (the FINGEN Study) (2010) (3)
- Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib (2021) (3)
- High Density Lipoprotein pathway as a therapeutic target for coronary heart disease: individual participant meta-analysis in 28,597 individuals with 4197 coronary events (2020) (3)
- Educating children about heart disease. (1994) (3)
- Corrigendum to “Cardio-metabolic risk factors and cortical thickness in a neurologically healthy male population: Results from the psychological, social and biological determinants of ill health (pSoBid) study” [Neuroimage Clin. 2 (2013) 646–57] (2015) (3)
- Studies of apolipoprotein B-100 metabolism using radiotracers and stable isotopes (1997) (3)
- The influence of dietary-fat saturation on the metabolism of apolipoproteins A-I, B and C in a type IIb hyperlipoproteinaemic subject (1978) (3)
- 3P-0786 Rosuvastatin: Kinetics of apoB-containing lipoproteins in moderate hypercholesterolemia (2003) (2)
- Effects of pnpla3 i148m on hepatic lipid and very low-density lipoprotein metabolism in humans. (2021) (2)
- Major statin trials : relationship between lipid changes and cardiovascular events (1999) (2)
- Obesity, metabolic syndrome and cardiovascular risk (2003) (2)
- The metabolism off apo B containing lipoproteins in a patient with hepatic lipase deficiency (1988) (2)
- Modelling total coronary heart disease burden and long-term benefit of cholesterol lowering in middle aged men with and without a history of cardiovascular disease (2017) (2)
- The pathophysiology of cholesterol metabolism in man (1985) (2)
- Cholesterol‐lowering Agents and their Use (2003) (2)
- Triglycerides and coronary risk. (1996) (2)
- CHAPTER 14 – Role of Lipoprotein-Associated Phospholipase A2 in Vascular Disease (2009) (2)
- Lipids and Atherosclerosis Annual 2003 (2003) (2)
- Risk factor modification after ACS Benefits of lipid regulation in acute coronary syndrome (2010) (2)
- Benefits of lipid regulation in acute coronary syndrome (2010) (2)
- Effects of drugs on postprandial lipoprotein metabolism (1997) (2)
- ‘N-terminal pro-B-type natriuretic peptide and the prediction of primary cardiovascular events: results from 15-year follow-up of WOSCOPS’ [Eur Heart J (2013); 34(6):443–450] (2013) (2)
- Lipoprotein metabolism and cardiovascular disease. (1987) (2)
- A solar heated and cooled office building (1976) (2)
- Abstract 814: CRP and Risk of Vascular Events in PROSPER (2006) (2)
- 4.P.231 Metabolism of triglyceride-rich lipoproteins determines occurrence of atherogenic LDL phenotype (1997) (2)
- 1.P.94 Characterisation of lipoprotein metabolism in the froxfield mixed hyperlipidaemic rabbit (1997) (2)
- Apolipoprotein (APO) B DNA polymorphism associated with differences in LDL metabolism (1987) (2)
- Lipoprotein-associated Phospholipase A2 (Lp PLA2), an inflammatory marker and novel independent risk factor in the West of Scotland Coronary Prevention Study (WOSCOPS) (2000) (2)
- Chapter 3. Lipoprotein Metabolism (1989) (1)
- A longitudinal study of the relationship between lipid, haemostatic and hormonal changes during normal human pregnancy (1998) (1)
- Genetics of hypercholesterolamemia: the detection of mutations in the apolipoprotein B gene using denaturing gradient gel electrophoresis. (1996) (1)
- The effect of pharmacological agents on low density lipoprotein subfractions (1995) (1)
- 1.P.153 Influence of pravatatin and plasma lipids on clinical events, in the West of Scotland Coronary Prevention Study (WOSCOPS) (1997) (1)
- Low-density-lipoprotein metabolism in type II hyperlipoproteinaemia. (1976) (1)
- THE RELATIONSHIP BETWEEN CIRCULATING MICRORNA AND LIPID INDICES (2016) (1)
- Poster abstractLDL subfraction metabolism in young healthy males (1994) (1)
- CD 36 and SR-BI Are Involved in Cellular Uptake of Provitamin A Carotenoids by Caco-2 and HEK Cells , and Some of Their Genetic Variants Are Associated with Plasma Concentrations of These Micronutrients in Humans 1 – 3 (2013) (1)
- Guidelines for clinical use of the statins (2003) (1)
- Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage (2014) (1)
- An investigation of the defect in type III hyperlipoproteinemia using agarose column chromatography. (1978) (1)
- The ABCA1 gene variant and heart disease risk reduction in the elderly during pravastatin treatment (2013) (1)
- The Reticuloendothelial System and Low Density Lipoprotein Metabolism (1986) (1)
- Cholesteryl ester transfer protein (CETP) Inhibition as a therapeutic strategy for raising HDL-cholesterol levels and reducing atherosclerosis (2003) (1)
- The hyperlipidaemia of normal pregnancy (1995) (1)
- Discovery of rare variants associated with blood pressure regulation through meta-analysis of 1.3 million individuals (2020) (1)
- Predictors of glucose intolerance (GI) in the West of Scotland Coronary Prevention Study (WOSCOPS) (2000) (1)
- LDL subfractions in non-insulin dependent diabetes mellitus (1993) (1)
- 4.W23.5 Is insulin regulation of VLDL production defective in insulin resistance (1997) (1)
- Metabolism of apolipoprotein B in primary moderate hypercholesterolaemia: effects of acipimox and cholestyramine therapy. (1995) (1)
- Metabolic syndrome and diabetes mellitus - Response. (2004) (1)
- Large scale trans-ethnic meta-analyses identify novel rare and common variants associated with blood pressure and hypertension (2016) (1)
- EFFECT OF PRAVASTATIN IN PEOPLE WITH CHRONIC KIDNEY DISEASE AND DIABETES MELLITUS: PD.8 (2005) (1)
- Mo-W1:5 Effect of rosuvastatin on remodelling of high-density lipoproteins in atherogenic dyslipidaemias: Role of cholesteryl ester transfer protein (CETP) (2006) (1)
- Plasma leptin levels and coronary heart disease - Response (2002) (1)
- Dementia and statins [1] (multiple letters) (2001) (1)
- Genetic and environmental modulation of low-density lipoprotein catabolism. (1990) (1)
- Role of endogenous incretins in the regulation of postprandial lipoprotein metabolism. (2022) (1)
- Pathophysiology of human lipoprotein receptors: clinical consequences of a cellular defect. (1984) (1)
- Effects of Lipid-Lowering Drugs on High Density Lipoprotein Structure and Metabolism (1987) (1)
- The computer revolution (1981) (1)
- Investigation of human apoB 48 metabolism using a new , integrated non-steady-state model of apoB 48 and apoB 100 kinetics (2019) (1)
- Pathogenesis of lipid abnormalities in patients with nephrotic syndrome/proteinuria: clinical implications. (1993) (1)
- The low-density-lipoprotein receptor pathway in familial hypercholesterolaemia: its role in pathogenesis and its response to therapy. (1983) (1)
- Do statins reduce the risk for diabetes by improving exercise capacity? Response (2001) (1)
- Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity (2019) (0)
- Metabolism of Human Triglyceride-rich Lipoprotein Remnants (1986) (0)
- An international perspective on cardiovascular risk management: recommendations for high-risk patients (2010) (0)
- Isolated CDH risk factors. (1993) (0)
- [Classification of hyperlipoproteinemia in the light of advances in pathogenetic studies]. (1985) (0)
- Ldl-C Lowering Among Patients With Ldl-C Above 4.9 Mmol/L And Features Suggesting A Genetic Vulnerability To Cardiovascular Disease: Analyses From The 4s Trial (2019) (0)
- New Perspectives in Human Apolipoprotein B Metabolism (1987) (0)
- Dextran Sulphate Adsorption: Effects on Coronary Heart Disease (1993) (0)
- FRI0134 Interleukin-6 Blockade Raises LDL via Reduced Catabolism Rather than via Increased Synthesis – A Cytokine-Specific Mechanism for Cholesterol Changes in Rheumatoid Arthritis (2016) (0)
- Association between serum concentrations of advanced glycation end products and C-reactive protein in type 2 diabetes mellitus (2003) (0)
- Lipid Metabolism and the Enterohepatic Circulation: The Regulatory Functions of HMG CoA Reductase and Cholesterol 7∝ Hydroxylase (1987) (0)
- Regression ofcoronary atherosclerosis: isitpossible? (2017) (0)
- Genetic Variants Related to Combined Exposure to both Lower Low- Density Lipoproteins and Lower Systolic Blood Pressure with Lifetime Risk of Cardiovascular Disease. JAMA Network Open, E1-E11 (2019) (0)
- Fibrates and Reversal of Atherogenic Particles (1992) (0)
- Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity (2018) (0)
- Preβ1-HDL as part of the lipoprotein spectrum and vascular disease (2014) (0)
- Genetics, Drugs and Low Density Lipoprotein Metabolism (1989) (0)
- Maintenance practices for gas turbines in power generation (1990) (0)
- Pravastatin and glucose intolerance (2000) (0)
- 1.P.30 Inhibition of lipolysis in isolated rat adipocytes (1997) (0)
- Cholesteryl ester transfer protein gene polymorphisms and high-density lipoprotein cholesterol. (1996) (0)
- Lipid metabolism and the enterohepatic circulation: the regulatory functions of HMG CoA reductase and cholesterol 7 alpha hydroxylase. (1987) (0)
- Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity (2018) (0)
- High-sensitivity cardiac troponin, statin threapy and risk of cardiovascular disease (2015) (0)
- Effects of dietary-fat saturation on the composition of very-low-density lipoproteins and on the metabolism of their major apoprotein, apolipoprotein B [proceedings]. (1978) (0)
- Peroxisome Proliferator Activated Receptor delta genotype in relation to cardiovascular risk factors and risk of coronary disease in hypercholesterolemic men (2002) (0)
- The Role of Receptors in Apolipoprotein B Metabolism (1983) (0)
- Identification ofa common lowdensity lipoprotein receptormutation (C163Y)inthe westofScotland (1998) (0)
- The effect of smoking on high density lipoprotein concentration and cholesteryl ester transfer protein activity in a healthy population (1993) (0)
- 2.P.182 Low density lipoprotein-associated phospholipase A2 (LDL-PLA2) as a risk factor for coronary artery disease (1997) (0)
- Lipid-lowering drug therapies: the evidence (2000) (0)
- Cholesterol and Coronary Heart Disease: the Current Status (2002) (0)
- Lipids and glycogen storage disease (2000) (0)
- P44 Use of Intralipid infusion to analyse apolipoprotein B (apoB) and HCV RNA kinetics in chronic infection (2011) (0)
- Goals of statin therapy: three viewpoints. 2002. (2004) (0)
- Receptors in the Regulation of Cholesterol Metabolism (1989) (0)
- New global standards in lipid lowering: a review of emerging evidence and concepts. (2002) (0)
- Diabetes in the West of Scotland Coronary Prevention Study Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart (2003) (0)
- Fibrinolytic markers in pregnancy: relationship to pertubations in lipoprotein levels (1995) (0)
- Publisher Correction: Discovery of rare variants associated with blood pressure regulation through meta-analysis of 1.3 million individuals (2021) (0)
- From genes and molecules to the bedside (1996) (0)
- The regulation of human low density lipoprotein subfraction distribution (1993) (0)
- Interaction of chylomicron remnants and VLDLs during ultracentrifuge separation based on the Svedberg flotation rate – Authors’ response (2020) (0)
- OP-EHEA170733 2546..2550 (2018) (0)
- Urinary Mevalonic Acid and Plasma Lathosterol: Responses to Simvastatin Therapy (1992) (0)
- The prognostic value for stroke of a nurse-led screening assessment of 71,527 Scottish middle-aged men (2001) (0)
- Lipoproteins and the pathogenesis of atherosclerosis : proceedings of the International Symposium on Lipoproteins and the Pathogenesis of Atherosclerosis, Gleneagles, Perthshire, 24-27 February 1991 (1991) (0)
- A comparison of two methods to investigate the metabolism of human apolipoproteins A-I and and A-I 1 (2002) (0)
- Statin therapy for the 21st century (2003) (0)
- Abstract P103: Genome-Wide Study of Gene Variants Associated with Differential Event Reduction by Pravastatin Therapy (2011) (0)
- Optimizing lipid-lowering therapy in the prevention of coronary heart disease (2010) (0)
- Reflections on a pioneer in the field of diet, lipids and vascular disease. (2015) (0)
- 4.P.199 VLDL subfraction metabolism during alimentary lipemia (1997) (0)
- High‐Risk Patients: Management Recommendations (2009) (0)
- Hyperlipidaemia as a risk factor for vascular heart disease (2003) (0)
- Motion 2: This house believes that the benefits of raising hdl cholesterol warrant its introduction as another lipid variable to target . Commentary (2002) (0)
- Lipoprotein metabolism: more than the sum of its parts. (1995) (0)
- Circulating microRNA-30C is associated with total- and LDL-cholesterol (2015) (0)
- 1,2 CYCLOHEXANEDIONE (CHD)-MODIFICATION OF HUMAN VERY LOW DENSITY LIPOPROTEIN (VLDL) SLOWS ITS CONVERSION TO LOW DENSITY LIPOPROTEIN (LDL) (1981) (0)
- Lipid-lowering regimes and exercise tolerance in subjects with angina (1990) (0)
- Developments in the dyslipidaemia of diabetes (2007) (0)
- Influence of fenofibrate on apo B metabolism in familial combined hyperlipidaemia (2000) (0)
- Management of hypercholesterol - aemia in the patient with diabetes (2002) (0)
- Socioeconomic Status and the Cerebellar Grey Matter Volume. Data from a Well-Characterised Population Sample (2013) (0)
- Management of hypercholesterolaemia. (1993) (0)
- A DIET-GENOTYPE INTERACTION OF LIPOPROTEIN METABOLISM IN RESPONSE TO FISH OIL SUPPLEMENTATION (2008) (0)
- The low density lipoprotein receptor pathway in animals and man. (1982) (0)
- The assessment of plasma lipoprotein metabolism in the cat (Felis domesticus) (1994) (0)
- 2.P.271 High plasma Lp(a) levels and low plasma HDL-cholesterol levels as risk factors for cerebrovascular disease in elderly men and women (1997) (0)
- Coronary heart disease telephone helpline: What the public want to know (1995) (0)
- Author response for "Effects of liraglutide on the metabolism of triglyceride-rich lipoproteins in type 2 diabetes" (2021) (0)
- Letter by Packard Regarding Article, "Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial". (2020) (0)
- Baseline lipid and lipoprotein concentrations in the participants of the prospective study of pravastatin in the elderly at risk (prosper) (2000) (0)
- Chapter 29 Mode of action of lipid-lowering drugs (1997) (0)
- Effects of insulin on very low density lipoprotein metabolism in normolipidaemic men (1995) (0)
- Drugs and high density lipoprotein metabolism. (1982) (0)
- Author response for "Role of apolipoprotein C‐III overproduction in diabetic dyslipidemia" (2019) (0)
- Relationship between achieved levels of LDL cholesterol and outcome in the west of Scotland coronary prevention study (WOSCOPS) (1999) (0)
- Abstract: 24 LDL LOWERING AND BEYOND IN CHD PREVENTION (2009) (0)
- Apoprotein exchange between human high-density-lipoprotein subfractions (high-density-lipoprotein subfractions 2 and 3) [proceedings]. (1978) (0)
- 3P-0761 Characterization of intermediate density lipoprotein particles that do and do not bind to chondroitin sulphate (2003) (0)
- New aspects to the pathophysiology of diabetic dyslipidemia (1999) (0)
- Differential binding of LDL subfractions to human arterial proteoglycan (1995) (0)
- Influence of etofibrate on human low density lipoprotein (ldl) metabolism (1987) (0)
- Trials and tribulations. (2002) (0)
- Pravastatin and glucose intolerance: Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study (2000) (0)
- Pragmatic coronary prevention, identifying patients at high risk of coronary heart disease (2002) (0)
- 4.P.266 VLDL triglyceride kinetics in mixed hyperlipidaemia (1997) (0)
- Abstract: P780 IS LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 IN HIGH DENSITY LIPOPROTEIN A RISK FACTOR FOR CORONARY VASCULAR DISEASE IN THE ELDERLY? (2009) (0)
- Metabolic channelling of apolipoprotein B in very low density lipoprotein. (1984) (0)
- CHD and diabetes reversing the trend (2004) (0)
- A middle-aged woman, being treated for hypercholesterolaemia, presents with abnormal liver function (1999) (0)
- [Molecular pathophysiology of familial hypercholesterolemia]. (1985) (0)
- C-Reactive Protein and Prediction of Coronary Heart Disease and Global Vascular Events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) Epidemiology (2007) (0)
- Lipid Lowering Therapy in Primary and Secondary Prevention: Insights from LIPID and WOSCOPS (1997) (0)
- Receptors in the regulation of lipoprotein metabolism. (1988) (0)
- Combined Exposure to both Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure with Lifetime Risk of Cardiovascular Disease. JAMA (2019) (0)
- Abstract: 35 GENE VARIANTS AND PRAVASTATIN LDL LOWERING RESPONSE IN PROSPER (2009) (0)
- WO2-OR-4 LIVER FAT INFLUENCES BOTH THE BASELINE PRODUCTION - AND THE ACUTE REGULATION OF VLDL1 TG AND APOB (2007) (0)
- Mo-W14:1 Novel approaches and new biomarkers for CHD risk assessment (2006) (0)
- Relationship between circulating microRNA-30c with lipoproteins, their circulatory trafficking and effect of statins (2016) (0)
- 2.W15.3 Optimal regulation of endogenous triglyceride-rich lipoprotein metabolism and the consequences of its failure for CHD risk (1997) (0)
- Oxidative modification of low density lipoprotein (LDL) subfractions as measured by fluorescence spectroscopy (1993) (0)
- [Antilipemic agents and postprandial lipidemia]. (1990) (0)
- Effect of sex and genotype on cardiovascular biomarker response to fish oils : the FINGEN Study 1 – 3 (2008) (0)
- Relative contribution of plasma small, dense LDL to coronary heart disease (CHD) risk (1995) (0)
- Pharmacologic modulation of the low density lipoprotein receptor pathway. (1988) (0)
- 2SS03-6 Improving outcomes — The ultimate aim (2003) (0)
- Kinetic studies of apolipoprotein B(apOB) in very low density lipoproteins(VLDL) in nephrotic hyperlipidaemia (1990) (0)
- Cross-reactivity between anti-apolipoprotein E antisera and retinal interphotoreceptor retinoid-binding protein (1988) (0)
- Pravastatin and coronary heart disease [3] (multiple letters) (1998) (0)
- Effects of fenofibrate on receptor-mediated and receptor-independent low density lipoprotein catabolism in hypertriglyceridaemic subjects. (1985) (0)
- Metabolic effects of hormone replacement preparations (1996) (0)
- Clinical Implications. (2018) (0)
- The pathogenesis of hyperlipoproteinaemia. (1986) (0)
- Effect of atorvastatin on lipids and lipoproteins in diabetic nephropathy (2001) (0)
- Stroke prevention in primary care (2003) (0)
- Chlorophenoxyisobutyric acid derivatives and apolipoprotein B metabolism. (1985) (0)
- Reports of Societies (1975) (0)
- The influence of dietary-fat saturation on the metabolism of apolipoproteins A-I, B and C in a type-IIb hyperlipoproteinaemic subject [proceedings]. (1978) (0)
- Abnormal suppression of 3-hydroxy-3-methylglutaryl-CoA reductase activity in cultured human fibroblasts by hypertriglyceridemic very low density lipoprotein subclasses (1980) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Christopher J. Packard?
Christopher J. Packard is affiliated with the following schools:
